NewAmsterdam Pharma (NAMSW) Receivables - Other (2023 - 2025)
Historic Receivables - Other for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to $3.9 million.
- NewAmsterdam Pharma's Receivables - Other rose 13687.73% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 13687.73%. This contributed to the annual value of $1.7 million for FY2024, which is 9977.14% up from last year.
- Per NewAmsterdam Pharma's latest filing, its Receivables - Other stood at $3.9 million for Q3 2025, which was up 13687.73% from $3.3 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Receivables - Other ranged from a high of $4.0 million in Q1 2024 and a low of $875000.0 during Q4 2023
- For the 3-year period, NewAmsterdam Pharma's Receivables - Other averaged around $2.4 million, with its median value being $1.9 million (2024).
- The largest annual percentage gain for NewAmsterdam Pharma's Receivables - Other in the last 5 years was 13687.73% (2025), contrasted with its biggest fall of 6381.43% (2025).
- Quarter analysis of 3 years shows NewAmsterdam Pharma's Receivables - Other stood at $875000.0 in 2023, then soared by 99.77% to $1.7 million in 2024, then skyrocketed by 123.05% to $3.9 million in 2025.
- Its Receivables - Other stands at $3.9 million for Q3 2025, versus $3.3 million for Q2 2025 and $1.4 million for Q1 2025.